Navigation Links
Karyopharm Therapeutics Inc. Appoints Michael Kauffman, MD, PhD, as Chief Executive Officer
Date:1/5/2011

NEWTON, Mass., Jan. 5, 2011 /PRNewswire/ -- Karyopharm Therapeutics Inc., a pioneer and leader in the new field of nuclear transport modulators, announces the recruitment of a highly experienced cancer drug developer, Michael G. Kauffman, MD, PhD, as its Chief Executive Officer. Dr. Kauffman will join Sharon Shacham, PhD, MBA, the Company's CSO and Head of Research and Development, as its executive management team. Kauffman's appointment follows the $20M Series A financing announced in November, 2010.

Karyopharm's lead program is focused on novel, small molecule SINE (Selective Inhibitors of Nuclear Export) targeting CRM1. CRM1 is a key linchpin governing the nuclear export of multiple tumor suppressors and growth regulatory proteins, providing a strategic point of therapeutic intervention for a diverse array of cancers. On joining Karyopharm, Kauffman, also a Karyopharm co-founder and Director, commented, "This is a rare opportunity to join a company firing on all cylinders -- strong funding, extremely promising lead compounds with broad and potent in vivo anti-tumor activity, a seasoned and committed scientific and development team, and leading cancer consultants. The clinical application, enabled further by sophisticated proprietary pharmacogenomic insights, offers the potential to transform cancer treatment with a new class of effective and well tolerated agents."  

According to Karyopharm Co-Founder, Board Member and Harvard cancer scientist Ronald A. DePinho, M.D., "The recruitment of Dr. Kauffman represents a major advance for Karyopharm which is now poised to bring a powerful new class of cancer medicines for diverse cancers and other diseases. Michael brings an extraordinary record of professional achievement in the development of major novel cancer drugs and in building and managing highly successful biotechnology companies."

Board member and clinical advisor Dr. Mansoor Raza Mirza commented, "It is depressing to see my patients dying short of an effective treatment. We badly need novel active and well tolerated drugs in our war against cancer. Karyopharm is determined to contribute meaningfully to this goal. I am confident that Michael with his immense experience, with the Karyopharm team, will lead the company to a success and we will have a powerful new approach to conquer this deadly disease."

Prior to joining Karyopharm, Dr. Kauffman was the chief medical officer of Onyx Pharmaceuticals Inc., which acquired Proteolix Inc., where he lead the development of carfilzomib, a novel proteasome inhibitor expected to be submitted for accelerated approval in refractory myeloma by Onyx as early as mid-2011. Dr. Kauffman was President and Chief Executive Officer of EPIX Pharmaceuticals, Inc. (previously Predix Pharmaceuticals, Inc.) from 2002 to 2008.  He was the leader of the Velcade® Development Program at Millennium Pharmaceuticals, and held a number of senior positions at Millennium Predictive Medicine and Biogen.  Dr. Kauffman received his MD and Ph.D. from Johns Hopkins Medical School and is board certified in internal medicine.

About Karyopharm Therapeutics Inc.Karyopharm is a privately held oncology company headquartered in Natick, Massachusetts, focused on the development of modulators of nuclear transport as novel therapies for cancer, inflammatory and other diseases. Drs. Sharon Shacham, Michael Kauffman, Ronald DePinho, and Giulio Draetta founded the company in 2009. The nuclear transport machinery plays an integral role in the regulation of many molecules involved in a broad spectrum of human and animal disease, and drug discovery has been enhanced with the recent determination of the 3-dimensional structure of the nuclear pore complex. Karyopharm is developing novel selective inhibitors of nuclear export (SINE) for the treatment of cancer, autoimmune diseases and HIV. These SINEs act by forcing the nuclear localization of key tumor suppressor and growth regulatory proteins causing the selective death of cancer cells while sparing normal cells. The Karyopharm platform, utilizing rapid chemical optimization with integrated computational/in silico rational drug design, has yielded multiple novel active small molecule SINEs, which have shown potent activity in animal models of cancer.  Additional programs focused on other aspects of nuclear export, as well as nuclear import, have been initiated.Contact: Michael Kaufmann617-803-0097mkauffman@karyopharm.com
'/>"/>

SOURCE Karyopharm Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Karyopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other Disorders
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
(Date:6/24/2016)... ... 24, 2016 , ... Puradigm® & Innovative Solutions today announced ... and processing operations at its production facility, and opened its first two dispensaries ... manufacturer of a complete system of proactive air and surface purification solutions for ...
Breaking Medicine News(10 mins):